About APCI

APCI logo

Not a member?
Join today!

(800) 532-2724

Since 1984, APCI has been the ‘united voice of independent pharmacy’

APCI began as a small buying group for a limited number of independent pharmacies in central Alabama. Since that time, the cooperative has grown to more than 1,800 members pharmacies in 26 states, and provides its members with a wide range of products and services.

Our mission is to represent the economic and professional interests of independent pharmacies by providing leadership, vision, and a collective voice for our members in the healthcare marketplace. Our goal is to level the playing field for our member pharmacies by providing innovative, targeted programs to benefit our entire membership.

19

Dec

2016

NCPA Advocacy Update 12.19.16

This week's Advocacy Update includes information on changes to the DEA's registrant renewal process, resources for states regarding Medicaid reform, and much more!

16

Dec

2016

Prime Therapeutics: Processing Update for Apparent Opioid Misuse for Medicare Part D Covered Persons

Effective January 1st 2017

Dear Valued Provider,

Effective January 1, 2017, Prime will be utilizing a new concurrent DUR (cDUR) service designed to help identify cases of Apparent Opioid Misuse. This service calculates the cumulative daily morphine equivalent dose (MED) across the submitted claim and selected historical claims. The service flags claims that would cause a Covered Person’s cumulative opioid medication use to exceed pre-defined thresholds of MED for consecutive days and associates with prescriptions from multiple Prescribing Providers filled by multiple Participating Pharmacies.

*Please see attached PDF for more information.

16

Dec

2016

OptumRx: Morphine Equivalent Dose Limit POS Edit (MEDLIMIT)

Effective January 1st 2017

Effective January 1, 2017, CMS will require Medicare plan sponsors to limit the daily cumulative dose of opioid products a member may obtain at Point of Sale (POS). The daily limit is referred to as the Morphine Equivalent Dose (MED) limit. The cumulative limit is based on a combination of drug strength and a product’s Morphine Milligram Equivalency (MME). The cumulative total daily MED value will be calculated based on the number of opioid drugs prescribed over a period of time which includes incoming claims and active claims history. Depending on the plan, there may be multiple MED limits with varying response levels (Soft or Hard reject).

*Please see attached PDF for more information.

16

Dec

2016

OptumRx: Opioid Use Following Buprenorphine (DDI POS Edit)

Effective January 1st 2017

Effective January 1, 2017, CMS will require Medicare plan sponsors to implement a soft point of sale (POS) reject when an opioid prescription is presented following the initiation of buprenorphine for the treatment of opioid use disorder. An enhancement to the Drug-Drug Interaction (DDI) cDUR edit will be turned on to reject opioid claims when a member has a recent history of treatment with buprenorphine or buprenorphine containing products indicated for opioid dependence.

*Please see attached PDF for more information.

15

Dec

2016

Express Scripts: Blue Cross Blue Shield of Louisiana - Closed Formulary Update

Effective January 1st 2017

Please note some Blue Cross and HMO Louisiana members will follow a new "closed" formulary, or Covered Drug List, effective January 1, 2017.

The new Covered Drug List (closed formulary) includes thousands of generic and brand drugs; however, not every drug will be covered. When a wide range of successful, lower-cost alternatives are available, higher-cost drugs may not be covered for members whose plans follow our new Covered Drug List. Members with this formulary have received a letter from Blue Cross Blue Shield of Louisiana (BCBSLA) explaining the change and where to find the list: www.bcbsla.com/CoveredDrugs. Members may also call the Pharmacy number on their ID card: 866.781.7533.

*Please see attached PDF for more information.

First 552553554555 Last